OUR
COMPANY

LTS our CompanyLTS our Company

OUR
COMPANY

We enable our partners to succeed by doing what we do best

Since 1984 we have been focused on utilizing our expertise, experience and innovation to create market leading drug delivery solutions for our pharmaceutical partners.

Our three-point purpose

LTS Claim - WE CARE. WE CREATE. WE DELIVER.
READ MORE

Our three-point purpose

LTS Claim - WE CARE. WE CREATE. WE DELIVER.
Read more

Our three-point outcomes

CREATING
new therapeutic opportunities
MAXIMISING
partner value
IMPROVING
patient outcomes

LTS in numbers

1.100

employees

800 Mio.

systems produced

300

patent families owned

Our major milestones

2019

The manufacturer’s authorisation for LTS is extended to the manufacturing of capsules.

2014

LTS manufactures the first OTF for the treatment of breakthrough pain in chronic cancer pain.

2013

Launch of an ondansetrone OTF for the treatment and prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy.

2012

Launch of the first ibuprofen patch, a local analgesic for the treatment of articular painful conditions, both traumatic and rheumatic.

2007

Launch of the first transdermal patch for the treatment of Alzheimer’s disease

2006

Launch of the first transdermal patch for the treatment of Parkinson’s disease

1990

The first nicotine patch for smoking cessation is launched in the US

1984

The first TTS matrix system from LTS achieves approval and is launched, a nitroglycerin patch.